Nasdaq
$4.21▲ 0.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $831.6MShares out 200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 3d agoPre-market26.10.22 20:318-KKey event#●●●#●●●
Arbutus Biopharma CorpBullish
Arbutus Biopharma announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for its oral PD-L1 inhibitor, AB-101. With this regulatory clearance, the company is now authorized to proceed with further clinical development of AB-101 in the United States.…more
$4.21+0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7After-hours26.10.08 05:35SCHEDULE 13G/AOwnership
Arbutus Biopharma Corp
Morgan Stanley and Morgan Stanley Investment Management Inc. have filed a joint Schedule 13G regarding their beneficial ownership in Arbutus Biopharma Corp (ABUS). Morgan Stanley confirms that the securities are held by its wholly-owned subsidiary, Morgan Stanley Investment Management Inc.…more
$4.21+0.24%vs prev closeView filingShare - 10.7After-hours26.10.08 05:124Ownership
Arbutus Biopharma Corp
Executive Robert A. Beardsley of Arbutus Biopharma Corp reported a change in beneficial ownership of securities as of October 1, 2026. This filing serves as a standard disclosure of insider transaction activity to the SEC.…more
$4.21+0.24%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoRegular26.10.22 23:25Bullish#●●●#●●●#●●●
FDA Lifts Clinical Hold on Arbutus Biopharma's Hepatitis B Drug
The FDA has lifted a three-year clinical hold on Arbutus Biopharma's investigational B-type hepatitis drug, AB-101. This regulatory clearance allows the company to resume clinical development of the candidate in the United States.…more
$4.21+0.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoPre-market26.10.22 20:30
●●●●●●●● ●●●●● ●●●●●●
Arbutus Biopharma announced that the FDA has lifted the clinical hold on its Investigational New Drug application for AB-101. This regulatory clearance allows the company to resume further clinical development of the oral PD-L1 inhibitor in the United States.…more
$4.21+0.24%vs prev close - 10.1Pre-market26.10.01 20:30
●●●●●●●● ●●●●● ●●●●●●
Arbutus Biopharma has finalized its $230 million tender offer through a modified Dutch auction. The company will cancel approximately 23% of its outstanding shares as part of its capital allocation strategy.…more
$4.21+0.24%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report